Chimeric antigen receptor (CAR) T cells have been approved for use in patients with B cell
malignancies or relapsed and/or refractory multiple myeloma, yet efficacy against most solid …

Malignant brain tumors, including glioblastoma, represent some of the most difficult to treat
of solid tumors. Nevertheless, recent progress in immunotherapy, across a broad range of …

Cell-based therapeutics have considerable promise across diverse medical specialties;
however, reliable human imaging of the distribution and trafficking of genetically engineered …

Imaging of T-cells and their responses during anti-cancer immunotherapy - PMC Back to Top
Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main …

Malignant brain tumors rank among the most challenging type of malignancies to manage.
The current treatment protocol commonly entails surgery followed by radiotherapy and/or …

Radioligand theranostics (RT) in oncology use cancer-type specific biomarkers and
molecular imaging (MI), including positron emission tomography (PET), single-photon …

The rapidly evolving field of cancer immunotherapy recently saw the approval of several
new therapeutic antibodies. Several cell therapies, for example, chimeric antigen receptor …

Chimeric antigen receptor T cell therapy (CAR-T) has been rolled out as a new treatment for
hematological malignancies. For solid tumor treatment, CAR-T has been disappointing so …

Cell therapies represent a rapidly emerging class of new therapeutics. They are intended
and developed for the treatment of some of the most prevalent human diseases, including …

Clinical monitoring of adoptive T cell transfer (ACT) utilizes serial blood analyses to discern
T cell activity. While useful, these data are 1-dimensional and lack spatiotemporal …